Nocion Therapeutics, Inc.’s Post

“We scrambled, got back, revived from the dead, if you will, and then worked again to bring in the right syndicate for this." Boston-area biotech Nocion Therapeutics, Inc. has raised $62 million to bring its capsule-based inhaler toward Phase III testing, CEO Rick Batycky told Endpoints News. The startup is attempting to treat chronic cough, a condition that lasts at least eight weeks and has become more stigmatized as a result of the Covid-19 pandemic. "It can make you feel like a social outcast,” said Julie Grant, a general partner at Nocion investor Canaan Partners. More on how Nocion plans to treat chronic cough with a different approach than GSK (by way of Bellus) and Merck: #cough #drugdevelopment #biotech #venturecapital